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Abstract
Atherosclerosis is one of the major causes of death. Data from animal experiments suggest that atherosclerosis
involves an inflammatory process of the vascular wall under hyperlipidemia. Atherothrombosis can become a
serious complication of atherosclerosis leading to acute cardiovascular events such as myocardial infarction and
stroke. Clinical applications to use this knowledge remain scarce. The plasma levels of vascular endothelium-
enriched microRNA (miRNAs) in patients with atherosclerotic vascular disease could serve as a disease marker. In
our laboratory vascular endothelium-enriched miRNA (miR-126) level was analyzed using quantitative RT
polymerase chain reaction analysis (qRT-PCR) in plasma from patients with suspected coronary artery disease (CAD)
according to the chest symptom or findings of electrocardiogram, or middle-aged male smokers. Endothelial
function for peripheral small vessels was assessed using End-PAT 2000 and expressed as reactive hyperemia
peripheral arterial tonometry (RH-PAT) index. In patients with suspected CAD miR-126 was not significantly changed
in CAD patients. However, miR-126 was decreased in CAD patients who also have high levels of low-density
lipoprotein (LDL) cholesterol. Interestingly, miR-126 was increased when LDL cholesterol was high in patients who
did not have evident CAD on coronary angiography even though they have risk factors for CAD. In smokers serum
cotinine levels were inversely correlated with endothelial function expressed as RH-PAT index and positively
correlated with levels of metabolic parameters such as non-high-density lipoprotein (HDL) cholesterol and insulin
resistance. More than half of the smokers could not completely attain smoking cessation and, thus, the RH-PAT
index was not improved 8 weeks after the instruction of smoking cessation. However, changes in the RH-PAT index
showed a significant correlation with those in systolic blood pressure. In smokers who completely attained smoking
cessation, both RH-PAT index and plasma miR-126 values were increased. Thus, among patients with suspected
CAD or subjects with coronary risk factors plasma levels of endothelium-enriched circulating miR-126 could be
substantially altered. The results suggest a potential usefulness of miR-126 as a sensitive biomarker in assessing
endothelial damage. Measurement of microRNA may serve as a useful tool for laboratory assays to determine high-
risk patients for atherothromobotic vascular diseases.
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Background
Coronary artery disease (CAD) is both a leading cause of
death and an important health threat in Asian countries
as well as in European countries. Markers for CAD in
circulation have been sought and identified. However,
only a few markers have important clinical implications.
Disease biomarkers that can appropriately evaluate the
risks for CAD and the early processes of atherosclerosis
are desirable. Circulating microRNAs (miRNAs) could be
useful candidates as disease biomarkers including cancer.
MiRNAs are a class of 20-25 nt single-stranded noncoding
RNAs. MiRNAs regulate cellular functions through
modulating mRNA degradation and repress translation of
mRNAs. MiRNAs regulate the gene expression regarding
cell growth, proliferation and apoptosis. MiRNAs are
found not only in tissues, but also in body fluids including
plasma. Circulating miRNAs remain in stable forms and
they are resistant to endogenous RNase. Therefore, the
signatures of miRNA in circulation can be useful in diag-
nosis, therapeutic efficacy and prognosis.
Review
Use of microRNA for biomedical research in thrombosis
Use of microRNA for biomedical research in throm-
bosis and hemostasis has provided substantial useful
information. Matsui et al. evaluated a modified lenti-
viral delivery strategy [1]. By incorporating miRNA tar-
get sequences they succeeded in facilitated transgene
expression in liver and prevented off-target expression
in hematopoietic cells. This system effectively restricted
transgene expression of coagulation factor VIII (FVIII) to
the liver. Level of FVIII in plasma was increased to 9 % of
normal level in the hemophilia A mice. Thrombin is
thrombogenic and mediates inflammation. Thrombin
induces activation and dysfunction of endothelial cells
through NF-kB and contributes to formation of arterial
thrombus. MiR-181b possesses anti-inflammatory actions
and inhibits downstream NF-kB signaling in response to
TNF-α. MiR-181b also inhibits upstream NF-kB signaling
induced by thrombin [2].
Dyslipidemia and microRNA
We measured circulating miRNA in CAD patients.
Significant CAD was confirmed by angiography. MiRNA
was also measured in patients without CAD [3]. This
study was approved by our institutional ethical commit-
tee. Informed consent was obtained from all partici-
pants. Dysfunction of endothelium is implicated in early
processes of atherosclerosis and thrombosis. Therefore,
vascular endothelium-enriched miRNA (miR-126) that
can potentially regulate angiogenesis was selected and
measured. CAD patients who showed higher levels of
myocardial stress marker, brain natriuretic peptide. Their
average New York Heart Association class, an index of
heart failure, was also higher. The prevalence of hyper-
tension and diabetes were similar between the 2 groups.
Patients without CAD showed lower prevalence of dys-
lipidemia. The lipid profiles were not significantly differ-
ent between the 2 groups due to anti-hyperlipidemic
drugs. Use of aspirin, α- blockers, angiotensin converting
enzyme inhibition/angiotensin receptor blockers, statin,
long-acting nitrates, insulin, and sulfonyl urea were less
frequent in patients without significant CAD. Use of
calcium channel blocker was not significantly different
between the 2 groups. The levels of miRNA in circula-
tion are relatively low. Thus, approach using microarray
may not be sensitive enough to identify miRNAs that
can serve as disease biomarkers. Therefore, quantitative
RT polymerase chain reaction (qRT-PCR) analysis was
utilized on RNA isolated from plasma. There are several
plasma miRNAs that were previously reported to have
altered levels in type 2 diabetes. We evaluated the candi-
date miRNAs. The analysis revealed that plasma miR-126
level of patients with CAD was comparable to the level of
patients without CAD. This result indicated that miR-126
was not a specific marker for CAD. We noticed that there
had been no report that level of miR-126 was influenced
by low-density lipoprotein (LDL) cholesterol. The level of
miR-126 was significantly decreased in CAD patients who
also showed high LDL cholesterol level. The miR-126 level
was increased in patients who had risk factors for CAD
and high level of LDL cholesterol but did not have CAD.
Taken together, our results suggested an association
between dysregulated plasma miR-126 and elevated levels
of LDL cholesterol in patients who have CAD.
Smoking, endothelial function and microRNA
We also determined microRNA in middle-age male
smokers [4]. Serum cotinine levels, a metabolite marker
of nicotine, were inversely correlated with endothelial
function expressed as reactive hyperemia peripheral
arterial tonometry (RH-PAT) index and high-density
lipoprotein (HDL)-cholesterol level, and positively corre-
lated with levels of non-HDL-cholesterol and homeosta-
sis model-insulin resistance (HOMA-IR). The smokers
were encouraged to stop smoking. The RH-PAT index
was not changed after 8 weeks in all subjects, because
only 13 subjects could attain smoking cessation, and
PH-PAT did not improve in 17 subjects who could not
attain smoking cessation. However, relative percent
change of systolic blood pressure was significantly corre-
lated with relative percent change of RH-PAT index.
Furthermore, subjects with decreased systolic blood
pressure exhibited significantly improved the RH-PAT
index. Next, smokers who completely attained smoking
cessation were analyzed separately. They indicated in-
creased RH-PAT ratio and plasma miR-126 after 8 weeks
of smoking cessation. However, RH-PAT index and
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expression levels of miR-126 did not show significant dif-
ference between subjects who completely attained 8 weeks
smoking cessation and subjects who could not attain
smoking cessation. These results suggested an association
between dysregulated plasma miR-126 level and vascular
endothelial damage in middle-age male smokers and
favorable effect of smoking cessation on recovery of endo-
thelial function and increase in miR-126 levels.
Platelets and microRNA for development of anti-
thrombotic drugs
Bray et al. investigated the platelet transcriptome in black
and white healthy subjects [5]. Platelet aggregation medi-
ated through PAR4 thrombin receptor was greater in
black subjects. Platelets from black subjects expressed
lower levels of miR-376c. Lower miR-376c contributed to
the higher expression of phosphatidylcholine transfer pro-
tein involved in platelet activation through thrombin.
These results may imply that a genomic contribution to
platelet function may differ by race. This difference may
partly explain the lower survival of blacks as compared to
whites after myocardial infarction due to coronary athero-
thrombosis. In the development of agents against throm-
bosis, one has to consider the effects of race.
Conclusions
MiRNAs emerged as new biomarkers useful for diagno-
sis and evaluation of pathophysiology of several athero-
thrombotic diseases. Standardization in samples, sample
processing and storage need care in the laboratory.
Technical protocols may become essential for the accur-
ate assessment of miRNAs as biomarkers.
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